KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ClearPoint Neuro (CLPT) EBT Margin (2018 - 2025)

ClearPoint Neuro's EBT Margin history spans 13 years, with the latest figure at 66.39% for Q3 2025.

  • For Q3 2025, EBT Margin fell 532.0% year-over-year to 66.39%; the TTM value through Sep 2025 reached 68.02%, down 824.0%, while the annual FY2024 figure was 62.91%, 3080.0% up from the prior year.
  • EBT Margin for Q3 2025 was 66.39% at ClearPoint Neuro, down from 63.07% in the prior quarter.
  • Across five years, EBT Margin topped out at 54.08% in Q1 2024 and bottomed at 119.85% in Q2 2023.
  • The 5-year median for EBT Margin is 73.75% (2022), against an average of 78.9%.
  • The largest annual shift saw EBT Margin plummeted -4650bps in 2021 before it soared 6394bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 96.8% in 2021, then rose by 11bps to 86.37% in 2022, then increased by 20bps to 69.1% in 2023, then decreased by -5bps to 72.68% in 2024, then increased by 9bps to 66.39% in 2025.
  • Per Business Quant, the three most recent readings for CLPT's EBT Margin are 66.39% (Q3 2025), 63.07% (Q2 2025), and 70.81% (Q1 2025).